About
Drugs to regulate hepcidin expression within the body
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyBoston & New England
Clinical Trials (9)
View allTotal Trials
9
As Lead Sponsor
9
As Collaborator
0
Total Enrollment
775
By Phase
PHASE1: 4PHASE2: 2PHASE3: 1PHASE2/PHASE3: 1PHASE1/PHASE2: 1
By Status
RECRUITING: 3COMPLETED: 3NOT_YET_RECRUITING: 1ENROLLING_BY_INVITATION: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07187973Lead Sponsor
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
PHASE1Not yet recruiting
24 participants
Started: Oct 31, 2025 · Completed: Oct 31, 2027
NCT06985147Lead Sponsor
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
PHASE2Recruiting
20 participants
Started: Aug 12, 2025 · Completed: Feb 28, 2029
NCT06910358Lead Sponsor
Study of Bitopertin in Participants With EPP or XLP (APOLLO)
PHASE3Recruiting
150 participants
Started: Apr 4, 2025 · Completed: Nov 30, 2026
NCT06050915Lead Sponsor
A Study of DISC-3405 in Healthy Volunteers
PHASE1Completed
64 participants
Started: Oct 3, 2023 · Completed: Jul 9, 2024
NCT05883748Lead Sponsor
Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with EPP
PHASE2/PHASE3Enrolling by invitation
200 participants
Started: Aug 31, 2023 · Completed: Jun 30, 2028
Locations (1)
Headquarters
Watertown, MA, United States
Map
Loading map...